JP2021512164A5 - - Google Patents

Info

Publication number
JP2021512164A5
JP2021512164A5 JP2020562093A JP2020562093A JP2021512164A5 JP 2021512164 A5 JP2021512164 A5 JP 2021512164A5 JP 2020562093 A JP2020562093 A JP 2020562093A JP 2020562093 A JP2020562093 A JP 2020562093A JP 2021512164 A5 JP2021512164 A5 JP 2021512164A5
Authority
JP
Japan
Prior art keywords
cells
cell line
tgf
pharmaceutical composition
tgfβi
Prior art date
Application number
JP2020562093A
Other languages
English (en)
Japanese (ja)
Other versions
JP7591406B2 (ja
JPWO2019152387A5 (https=
JP2021512164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015617 external-priority patent/WO2019152387A1/en
Publication of JP2021512164A publication Critical patent/JP2021512164A/ja
Publication of JP2021512164A5 publication Critical patent/JP2021512164A5/ja
Publication of JPWO2019152387A5 publication Critical patent/JPWO2019152387A5/ja
Priority to JP2024200825A priority Critical patent/JP2025026937A/ja
Application granted granted Critical
Publication of JP7591406B2 publication Critical patent/JP7591406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020562093A 2018-01-30 2019-01-29 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞 Active JP7591406B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024200825A JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623682P 2018-01-30 2018-01-30
US62/623,682 2018-01-30
PCT/US2019/015617 WO2019152387A1 (en) 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024200825A Division JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Publications (4)

Publication Number Publication Date
JP2021512164A JP2021512164A (ja) 2021-05-13
JP2021512164A5 true JP2021512164A5 (https=) 2022-01-27
JPWO2019152387A5 JPWO2019152387A5 (https=) 2022-01-27
JP7591406B2 JP7591406B2 (ja) 2024-11-28

Family

ID=67478491

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562093A Active JP7591406B2 (ja) 2018-01-30 2019-01-29 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞
JP2024200825A Pending JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024200825A Pending JP2025026937A (ja) 2018-01-30 2024-11-18 トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞

Country Status (12)

Country Link
US (1) US20200368281A1 (https=)
EP (1) EP3746118A4 (https=)
JP (2) JP7591406B2 (https=)
KR (2) KR20250093419A (https=)
CN (1) CN111818941A (https=)
AU (1) AU2019213678B2 (https=)
BR (1) BR112020015490A2 (https=)
CA (1) CA3090096A1 (https=)
IL (2) IL276374B2 (https=)
MX (1) MX2020008044A (https=)
SG (1) SG11202007288VA (https=)
WO (1) WO2019152387A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517220A (ja) * 2020-03-11 2023-04-24 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
AU2021263579A1 (en) * 2020-04-30 2022-12-01 Research Institute At Nationwide Children's Hospital Overcoming immune suppression with TGF-β resistant NK cells
KR20250154429A (ko) * 2023-03-02 2025-10-28 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 암 면역요법을 위한 형질전환 성장인자-베타 슈퍼패밀리가 각인된 자연살해세포

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
WO2015103793A1 (zh) * 2014-01-13 2015-07-16 深圳市汉科生物工程有限公司 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法
EP3223856B1 (en) 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
KR20180040706A (ko) * 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using

Similar Documents

Publication Publication Date Title
Taefehshokr et al. Promising approaches in cancer immunotherapy
Zhang et al. Interplay between inflammatory tumor microenvironment and cancer stem cells
DE69919869T2 (de) Stimulierung des immunsystems
JP7770929B2 (ja) Ｃａｒ－ｔ細胞のインサイチュ動員、リプログラミングおよび放出
JP2021512164A5 (https=)
JP2004525957A5 (https=)
DE60036019T2 (de) Synthetische oligonukleotide die therapeutisch nützlich sind
DE10335833A1 (de) Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
KR20050005521A (ko) 면역자극 올리고뉴클레오티드 및 그의 용도
EP2658566A1 (de) Sirna gegen cbl-b und optional il2 und il12 zur verwendung in der behandlung von krebs
KR20130126680A (ko) 비-코딩 면역조절 dna 구조체
WO2006015560A1 (de) Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
EP0281380A2 (en) Synergistic interplay of interleukin-2 and dsRNAs
KR20100126390A (ko) 톨-유사 수용체 3의 선택적인 작용제
IL276374B2 (en) Transforming growth factor beta-resistant natural killer cells
Chou et al. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles
JPWO2019152387A5 (https=)
Egilmez et al. Controlled-release particulate cytokine adjuvants for cancer therapy
US20160113966A1 (en) Composition and methods of culture supernatant of khyg-1 cells
Zöller et al. Interleukin‐1 produced by tumorigenic fibroblasts influences tumor rejection
CN106928298B (zh) 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用
Paillard Cytokine and chemokine: a stimulating couple
Pitton et al. Different regulation of TNF alpha and IL-1ra synthesis in LPS-tolerant human monocytes
Wu et al. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells
CN112569359A (zh) 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用